Suppressing ‘nonsense’ in cystic fibrosis

Volume: 598, Issue: 3, Pages: 429 - 430
Published: Jan 16, 2020
Abstract
With the clinical approval of Trikafta (elexacaftor-tezacaftor-ivacaftor) (https://www.fda.gov/news-events/press-announcements/fda-approves-new-breakthrough-therapy-cystic-fibrosis), most people with cystic fibrosis (CF) have a drug therapy targeting the root cause of their disease, mutations in the epithelial anion channel cystic fibrosis transmembrane conductance regulator (CFTR). However, the fight against CF is certainly not over. Now,...
Paper Details
Title
Suppressing ‘nonsense’ in cystic fibrosis
Published Date
Jan 16, 2020
Volume
598
Issue
3
Pages
429 - 430
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.